Phase I trial of CD19 CAR-T cells with a PD1/CD28 switch receptor for relapsed or refractory B-cell lymphoma
CD19 CAR-T therapy achieves high remission rates in relapsed/refractory (R/R) B-cell lymphoma but is often limited by PD1/PD-L1–mediated immune suppression. A PD1/CD28 switch receptor may convert inhibitory PD1 signals into CD28 costimulation, enhancing efficacy. In this single-center, phase I trial, adults with R/R B-cell lymphoma received autologous CD19 CAR-T cells incorporating a PD1/CD28 switch receptor. Treatment followed a 3 + 3 dose-escalation design with subsequent expansion cohorts. Primary endpoints were safety and feasibility; secondary endpoints included efficacy, survival, CAR-T kinetics, and biomarker correlations. Thirty-two patients received CAR-T cells. In dose escalation, 6/9 responded (overall response rate [ORR] 66.7%; complete response [CR] 44.4%). Based on favorable responses at the highest dose (3 × 10^6/kg), 23 additional patients were treated, yielding ORR 87.0% and CR 69.6%. At median follow-up of 34 months, median duration of response (DOR) and overall survival (OS) were not reached; 12- and 36-month DOR rates were 58.6% and 53.3%. Median progression-free survival (PFS) was 12 months, with 3-year PFS 43.3%; 1- and 3-year OS were 82% and 64%. Cytokine release syndrome occurred in 62.5% (all grade 1–2) and neurotoxicity in 6.3% (grade 2–3). No significant association was detected between baseline PD-L1 expression and response. CD19&PD1/CD28 CAR-T therapy achieved high response rates, durable remissions, and manageable toxicity in R/R B-cell lymphoma. Responses occurred across baseline PD-L1 strata, but the single-arm design precludes attribution of efficacy to the switch receptor. Trial registration ClinicalTrials.gov Identifier NCT03932955.
Authors
- Jun Zhu (ORCID: https://orcid.org/0000-0002-0859-3483)
- Yingchi Zhao (ORCID: https://orcid.org/0000-0002-8698-6864)
- Shance Li
- Chaoting Zhang (ORCID: https://orcid.org/0000-0002-2094-9171)
- Li Qu
- Yongjing Tang
- Tingting Du (ORCID: https://orcid.org/0000-0002-9432-2021)
- Ningjing Lin
- Luyan Shen
- Bo Ma
- Yuqin Song
- Yan Xie
- Zheming Lu
- Wen Zheng
Institutions
- Peking University Cancer Hospital (CN)
- Ministry of Education (ET)
Publication Details
- Journal
- Experimental Hematology and Oncology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s40164-026-00866-1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00